Market Overview

Arena Pharmaceuticals Initiates Phase 1 Multiple Dose Clinical Trial of APD811 for Pulmonary Arterial Hypertension

Share:
Related ARNA
Wednesday's Mid-Day Movers: Does The U.S. Benefit From Iran Deal?; Celgene-Receptos And More
Mid-Morning Market Update: Markets Mostly Higher; Bank Of America Tops Q2 Views
Arena's Phase 2 Trial An Opportunity For Improved Valuation (Seeking Alpha)

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of dosing in a Phase 1 multiple dose clinical trial of APD811, a novel oral drug candidate discovered by Arena that targets the prostacyclin (IP) receptor for the treatment of pulmonary arterial hypertension (PAH).

This randomized, double-blind and placebo-controlled dose titration trial is planned to enroll up to 30 healthy adult volunteers, and will evaluate the safety, tolerability and pharmacokinetics of multiple-ascending doses of APD811 and the optimal titration schedule. Arena previously evaluated single-ascending doses of APD811 in the initial Phase 1 clinical trial.

Posted-In: News FDA

 

Related Articles (ARNA)

Get Benzinga's Newsletters